|
1
|
WILD BWSCP: World Cancer Report:
International Agency for Research on Cancer. 978-992-832-0443-5.
2014.
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Board., P.A.T.E., PDQ Adult Treatment
Editorial Board, . Colon Cancer Treatment (PDQ®):
Patient Version. PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2016
|
|
4
|
Suzuki A, Lu J, Kusakai G, Kishimoto A,
Ogura T and Esumi H: ARK5 is a tumor invasion-associated factor
downstream of Akt signaling. Mol Cell Biol. 24:3526–3535. 2004.
View Article : Google Scholar
|
|
5
|
Suzuki A, Kusakai G, Kishimoto A, Lu J,
Ogura T and Esumi H: ARK5 suppresses the cell death induced by
nutrient starvation and death receptors via inhibition of caspase 8
activation, but not by chemotherapeutic agents or UV irradiation.
Oncogene. 22:6177–6182. 2003. View Article : Google Scholar
|
|
6
|
Suzuki A, Kusakai G, Kishimoto A, Shimojo
Y, Miyamoto S, Ogura T, Ochiai A and Esumi H: Regulation of
caspase-6 and FLIP by the AMPK family member ARK5. Oncogene.
23:7067–7075. 2004. View Article : Google Scholar
|
|
7
|
Suzuki A, Kusakai G, Shimojo Y, Chen J,
Ogura T, Kobayashi M and Esumi H: Involvement of transforming
growth factor-beta 1 signaling in hypoxia-induced tolerance to
glucose starvation. J Biol Chem. 280:31557–31563. 2005. View Article : Google Scholar
|
|
8
|
Suzuki A, Ogura T and Esumi H: NDR2 acts
as the upstream kinase of ARK5 during insulin-like growth factor-1
signaling. J Biol Chem. 281:13915–13921. 2006. View Article : Google Scholar
|
|
9
|
Chang XZ, Yu J, Liu HY, Dong RH and Cao
XC: ARK5 is associated with the invasive and metastatic potential
of human breast cancer cells. J Cancer Res Clin Oncol. 138:247–254.
2012. View Article : Google Scholar
|
|
10
|
Cui J, Yu Y, Lu GF, Liu C, Liu X, Xu YX
and Zheng PY: Overexpression of ARK5 is associated with poor
prognosis in hepatocellular carcinoma. Tumor Biol. 34:1913–1918.
2013. View Article : Google Scholar
|
|
11
|
Sun X, Gao L, Chien HY, Li WC and Zhao J:
The regulation and function of the NUAK family. J Mol Endocrinol.
51:R15–R22. 2013. View Article : Google Scholar
|
|
12
|
Lu S, Niu N, Guo H, Tang J, Guo W, Liu Z,
Shi L, Sun T, Zhou F, Li H, et al: ARK5 promotes glioma cell
invasion and its elevated expression is correlated with poor
clinical outcome. Eur J Cancer. 49:752–763. 2013. View Article : Google Scholar
|
|
13
|
Suzuki A, Iida S, Kato-Uranishi M, Tajima
E, Zhan F, Hanamura I, Huang Y, Ogura T, Takahashi S, Ueda R, et
al: ARK5 is transcriptionally regulated by the Large-MAF family and
mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a
new molecular determinant of malignant multiple myeloma. Oncogene.
24:6936–6944. 2005. View Article : Google Scholar
|
|
14
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
|
|
15
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci
USA. 92:pp. 5510–5514. 1995; View Article : Google Scholar
|
|
16
|
Semenza GL: Defining the role of
hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 29:625–634. 2010. View Article : Google Scholar
|
|
17
|
Wang JS, Jing CQ, Shan KS, Chen YZ, Guo
XB, Cao ZX, Mu LJ, Peng LP, Zhou ML and Li LP: Semaphorin 4D and
hypoxia-inducible factor-1α overexpression is related to prognosis
in colorectal carcinoma. World J Gastroenterol. 21:2191–2198. 2015.
View Article : Google Scholar
|
|
18
|
Amin MB, Greene FL, Edge S, et al: AJCC
cancer staging manual. 8th. New York: Springer; pp. 1–274. 2017
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Kong D, Su G, Zha L, Zhang H, Xiang J, Xu
W, Tang Y and Wang Z: Coexpression of HMGA2 and Oct4 predicts an
unfavorable prognosis in human gastric cancer. Med Oncol.
31:1302014. View Article : Google Scholar
|
|
21
|
Xu T, Zhang J, Chen W, Pan S, Zhi X, Wen
L, Zhou Y, Chen BW, Qiu J, Zhang Y, et al: ARK5 promotes
doxorubicin resistance in hepatocellular carcinoma via
epithelial-mesenchymal transition. Cancer Lett. 377:140–148. 2016.
View Article : Google Scholar
|
|
22
|
Kusakai G, Suzuki A, Ogura T, Miyamoto S,
Ochiai A, Kaminishi M and Esumi H: ARK5 expression in colorectal
cancer and its implications for tumor progression. Am J Pathol.
164:987–995. 2004. View Article : Google Scholar
|
|
23
|
Shin DH, Choi YJ and Park JW: SIRT1 and
AMPK mediate hypoxia-induced resistance of non-small cell lung
cancers to cisplatin and doxorubicin. Cancer Res. 74:298–308. 2014.
View Article : Google Scholar
|
|
24
|
Mitani T, Ito Y, Harada N, Nakano Y, Inui
H, Ashida H and Yamaji R: Resveratrol reduces the hypoxia-induced
resistance to doxorubicin in breast cancer cells. J Nutr Sci
Vitaminol (Tokyo). 60:122–128. 2014. View Article : Google Scholar
|
|
25
|
Casazza A, Di Conza G, Wenes M,
Finisguerra V, Deschoemaeker S and Mazzone M: Tumor stroma: A
complexity dictated by the hypoxic tumor microenvironment.
Oncogene. 33:1743–1754. 2014. View Article : Google Scholar
|
